BioXcel Therapeutics Inc logo

BTAI - BioXcel Therapeutics Inc Share Price

$45.17 -3.4  -7.1%

Last Trade - 8:25pm

Sector
Healthcare
Size
Mid Cap
Market Cap £900.7m
Enterprise Value £839.3m
Revenue £n/a
Position in Universe 2254th / 6393
Bullish
Bearish
Unlock BTAI Revenue
Momentum
Relative Strength (%)
1m -14.4%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -32.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 8.67
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2020, BioXcel Therapeutics Inc revenues was not reported. Net loss increased from $7.2M to $14.9M. Higher net loss reflects Research and development increase from $5.7M to $12.4M (expense), General and administrative increase of 50% to $2.6M (expense), Dividend and interest income, net decrease of 60% to $85K (income). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.46 to -$0.79.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for BTAI
Graphical History

Revenue

BTAI Revenue Unlock BTAI Revenue

Net Income

BTAI Net Income Unlock BTAI Revenue

Normalised EPS

BTAI Normalised EPS Unlock BTAI Revenue

PE Ratio Range

BTAI PE Ratio Range Unlock BTAI Revenue

Dividend Yield Range

BTAI Dividend Yield Range Unlock BTAI Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BTAI EPS Forecasts Unlock BTAI Revenue
Profile Summary

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company that is focused on the development of drugs for psychiatric disorders and rare cancers. The Company uses novel artificial intelligence (AI) for drug re-innovation processes of approved product candidates to identify new therapeutic indices. Its principal clinical development programs are BXCL501 and BXCL701. BXCL501 is a sublingual thin film formulation of dexmedetomidine (Dex) designed for the acute treatment of agitation resulting from neurological and psychiatric disorders. BXCL701 is an immuno-oncology agent designed for the treatment of prostate and pancreatic cancer.

Directors
Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated March 29, 2017
Public Since March 8, 2018
No. of Shareholders: 11
No. of Employees: 27
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 24,182,382
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BTAI Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BTAI
Upcoming Events for BTAI
Friday 14th August, 2020
Q2 2020 BioXcel Therapeutics Inc Earnings Call
Frequently Asked Questions for BioXcel Therapeutics Inc
What is the BioXcel Therapeutics Inc share price?

As of 8:25pm, shares in BioXcel Therapeutics Inc are trading at $45.17, giving the company a market capitalisation of £900.7m. This share price information is delayed by 15 minutes.

How has the BioXcel Therapeutics Inc share price performed this year?

Shares in BioXcel Therapeutics Inc are currently trading at $45.17 and the price has moved by 0.447k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the BioXcel Therapeutics Inc price has moved by 0.377k% over the past year.

What are the analyst and broker recommendations for BioXcel Therapeutics Inc?

Of the analysts with advisory recommendations for BioXcel Therapeutics Inc, there are there are currently 2 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for BioXcel Therapeutics Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will BioXcel Therapeutics Inc next release its financial results?

BioXcel Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the BioXcel Therapeutics Inc dividend yield?

BioXcel Therapeutics Inc does not currently pay a dividend.

Does BioXcel Therapeutics Inc pay a dividend?

BioXcel Therapeutics Inc does not currently pay a dividend.

When does BioXcel Therapeutics Inc next pay dividends?

BioXcel Therapeutics Inc does not currently pay a dividend.

How do I buy BioXcel Therapeutics Inc shares?

To buy shares in BioXcel Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of BioXcel Therapeutics Inc?

Shares in BioXcel Therapeutics Inc are currently trading at $45.17, giving the company a market capitalisation of £900.7m.

Where are BioXcel Therapeutics Inc shares listed? Where are BioXcel Therapeutics Inc shares listed?

Here are the trading details for BioXcel Therapeutics Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: BTAI
What kind of share is BioXcel Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, BioXcel Therapeutics Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a BioXcel Therapeutics Inc share price forecast 2020?

Shares in BioXcel Therapeutics Inc are currently priced at $45.17. At that level they are trading at 0.137% discount to the analyst consensus target price of 0.00.

Analysts covering BioXcel Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -3.05 for the next financial year.

How can I tell whether the BioXcel Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioXcel Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been 0.143k%. At the current price of $45.17, shares in BioXcel Therapeutics Inc are trading at 71.11% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the BioXcel Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for BioXcel Therapeutics Inc.

Who are the key directors of BioXcel Therapeutics Inc?

BioXcel Therapeutics Inc's management team is headed by:

Vimal Mehta - PRE
Vincent O'Neill - OTH
Richard Steinhart - CFO
Frank Yocca - CSO
Luca Rastelli - VPR
Chids Mahadevan - VFN
Peter Mueller - CHM
Sandeep Laumas - IND
Krishnan Nandabalan - CFD
Vikas Sharma - VBD
Robert Risinger - VPR
Michal Votruba - IND
Will Kane - EVP
Reina Benabou - SVP
Who are the major shareholders of BioXcel Therapeutics Inc?

Here are the top five shareholders of BioXcel Therapeutics Inc based on the size of their shareholding:

Bioxcel Corp Corporation
Percentage owned: 37.96% (9.18m shares)
DNCA Invest - Beyond Global Leaders Mutual Fund
Percentage owned: 4.14% (1.00m shares)
DNCA Investments Investment Advisor
Percentage owned: 3.69% (892k shares)
SPDR S&P Biotech ETF Mutual Fund
Percentage owned: 3.52% (852k shares)
Artemis Investment Management LLP Investment Advisor/Hedge Fund
Percentage owned: 2.9% (701k shares)
Similar to BTAI
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.